Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma

Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study

(2021) Kevin C. Oeffinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

(2021) Monika L. Metzger et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

(2021) David J Straus et al.   Lancet Haematology

Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial

(2021) Christine Mauz-Körholz et al.   LANCET ONCOLOGY

Survival by age in paediatric and adolescent patients with Hodgkin lymphoma: a retrospective pooled analysis of children's oncology group trials

(2021) Justine M Kahn et al.   Lancet Haematology

Response‐adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group

(2019) Kara M. Kelly et al.   BRITISH JOURNAL OF HAEMATOLOGY

Closing the survivorship gap in children and adolescents with Hodgkin lymphoma

(2019) Sharon M. Castellino et al.   BRITISH JOURNAL OF HAEMATOLOGY

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

(2018) Joseph M. Connors et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial

(2018) Peter D Cole et al.   LANCET ONCOLOGY

Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma

(2016) Jamie E. Flerlage et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

(2016) Peter Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group Study AHOD0031

(2014) Debra L. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Measuring Vincristine-Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia

(2013) Ellen M. Lavoie Smith et al.   CANCER NURSING

Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma

(2012) Kara M. Kelly et al.   PEDIATRIC BLOOD & CANCER

Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study

(2010) S. M. Castellino et al.   BLOOD

Report on the First International Workshop on interim-PET scan in lymphoma

(2009) Michel Meignan et al.   LEUKEMIA & LYMPHOMA